COPD killed 138,825 Americans in a single year, sixth on the national list.1

Patients already taking triple inhaled therapy still average 1.1 moderate or severe exacerbations annually.2

An entire generation of respiratory biologics has passed over the majority of COPD patients. That majority is who we are building for.

Please note: Axenil Labs operates in a stealth capacity.

This goes to the founding team, not to a list. Your details go no further than the reply. Privacy notice.